148 related articles for article (PubMed ID: 33788759)
1. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Anticancer Res; 2021 Mar; 41(3):1629-1639. PubMed ID: 33788759
[TBL] [Abstract][Full Text] [Related]
2. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Pancreas; 2021 May-Jun 01; 50(5):744-750. PubMed ID: 34016892
[TBL] [Abstract][Full Text] [Related]
4. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
[TBL] [Abstract][Full Text] [Related]
6. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy.
Sugawara T; Rodriguez Franco S; Sherman S; Kirsch MJ; Colborn K; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
JAMA Oncol; 2023 Mar; 9(3):316-323. PubMed ID: 36480190
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
8. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective.
Kurata Y; Shiraki T; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2021 Mar; 19(1):85. PubMed ID: 33752677
[TBL] [Abstract][Full Text] [Related]
9. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study.
Sakamoto T; Kishino M; Murakami Y; Miyatani K; Hanaki T; Shishido Y; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Fujiwara Y
Medicine (Baltimore); 2024 May; 103(21):e38292. PubMed ID: 38788030
[TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
Kitano Y; Inoue Y; Takeda T; Oba A; Ono Y; Sato T; Ito H; Ozaka M; Sasaki T; Sasahira N; Baba H; Takahashi Y
Ann Surg Oncol; 2023 Aug; 30(8):5093-5102. PubMed ID: 37140750
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study.
Pu N; Wu W; Liu S; Xie Y; Yin H; Chen Q; He T; Xu Z; Wang W; Yu J; Liu L; Lou W
Int J Surg; 2023 Oct; 109(10):3137-3146. PubMed ID: 37418574
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma.
Matsushima H; Adachi T; Hidaka M; Yamashita M; Hamada T; Fukui S; Tanaka T; Imamura H; Yoshino K; Kugiyama T; Kitasato A; Hara T; Soyama A; Kobayashi K; Sumida Y; Kuroki T; Eguchi S
Anticancer Res; 2022 Jun; 42(6):3133-3141. PubMed ID: 35641261
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
[TBL] [Abstract][Full Text] [Related]
14. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
[TBL] [Abstract][Full Text] [Related]
15. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma.
Kawahara K; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
Clin Exp Metastasis; 2022 Apr; 39(2):311-322. PubMed ID: 35000025
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
Kim SS; Ko AH; Nakakura EK; Wang ZJ; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Kim GE
Am J Surg Pathol; 2019 Mar; 43(3):334-340. PubMed ID: 30211728
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
[TBL] [Abstract][Full Text] [Related]
18. Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma.
Takaori A; Hashimoto D; Ikeura T; Ito T; Nakamaru K; Masuda M; Nakayama S; Yamaki S; Yamamoto T; Fujimoto K; Matsuo Y; Akagawa S; Ishida M; Yamaguchi K; Imoto S; Hirota K; Uematsu S; Satoi S; Sekimoto M; Naganuma M
Pancreatology; 2023 Jun; 23(4):367-376. PubMed ID: 37088586
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma in Elderly Patients: Special Reference to Postoperative Adjuvant Chemotherapy.
Watanabe Y; Shinkawa T; Endo S; Abe Y; Nishihara K; Nakano T
World J Surg; 2018 Aug; 42(8):2617-2626. PubMed ID: 29383429
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
